Suppression of allergen reactive Th2 mediated responses and pulmonary eosinophilia by intranasal administration of an immunodominant peptide is linked to IL-10 production

The potential to induce systemic tolerance following exposure of the airway mucosa to soluble antigen, may be applied therapeutically for the treatment of allergic disease. Since the use of allergen can trigger IgE mediated inflammation, we investigated whether mucosal delivery of a peptide, contain...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2003-01, Vol.21 (5), p.549-561
Main Authors: Hall, Gillian, Houghton, Christian G., Rahbek, Janne Uldal, Lamb, Jonathan R., Jarman, Elizabeth R.
Format: Article
Language:English
Subjects:
Allergens - immunology
Allergies
Allergy
Animals
Asthma - pathology
Biological and medical sciences
Biotechnology
Bronchoalveolar Lavage Fluid - cytology
Cloning
Dermatophagoides farinae - immunology
Dermatophagoides pteronyssinus
Eosinophils - immunology
Fundamental and applied biological sciences. Psychology
Health. Pharmaceutical industry
Immune Tolerance - immunology
Immunity, Cellular - immunology
Immunization
Immunodominant Epitopes - immunology
Immunoregulation
In vivo animal models
Industrial applications and implications. Economical aspects
Interleukin-10 - biosynthesis
Interleukin-13 - biosynthesis
Interleukin-4 - biosynthesis
Interleukin-5 - biosynthesis
Leukocyte Count
Lung - cytology
Lymphocytes
Mice
Mice, Inbred C57BL
Microencapsulated antigen
Peptides
Peptides - immunology
Population
Production of active biomolecules
Pulmonary Eosinophilia - immunology
Pulmonary Eosinophilia - metabolism
Pulmonary Eosinophilia - prevention & control
Rodents
Studies
Th1 Cells - immunology
Th2 Cells - immunology
Vaccins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The potential to induce systemic tolerance following exposure of the airway mucosa to soluble antigen, may be applied therapeutically for the treatment of allergic disease. Since the use of allergen can trigger IgE mediated inflammation, we investigated whether mucosal delivery of a peptide, containing an immunodominant epitope of the Der p1 allergen of house dust mite, can lead to CD4 + Th2 cell tolerance and thus protect against airway inflammatory responses to inhalant allergen. The administration of microencapsulated peptide to the nasal mucosa of mice, protected against airway inflammation, with significant reductions in eosinophil infiltration into the airways following allergen challenge. Der p1 specific antibody levels in sera were not modulated. Allergen reactive CD4 + T cells expressed a tolerized phenotype, with reduction in levels of the cytokines, IL-5, IL-13 and IFN-γ although IL-10 levels were increased. The mucosal administration of a peptide containing an immunodominant region of an allergen can protect against the induction of systemic and local inflammatory responses to allergen challenge.
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(02)00394-8